PMA device
Restylane® Lyft with Lidocaine
Q-Med AB · Implant, Dermal, For Aesthetic Use (LMH, Class III) · First FDA decision Nov 2, 2018, newest Dec 23, 2025Aesthetic skin, fat and body contouring
Last checked: Nov 20, 2026Source: FDA, CMS, ClinicalTrials.gov, PubMed
FDA decisions
4
PMA pathway
Device trials
20
Naming "Restylane Lyft"
MAUDE reports
201
Brand "Restylane Lyft", since 2015
PubMed studies
27
Mentioning "Restylane Lyft"
AI summary across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, MAUDE and PubMed data on this page, plus web searches for payment facts.
Product review deck
A slide deck reviewing Restylane® Lyft with Lidocaine
About ten slides on the technology, clinical evidence, regulatory history and commercialization, built with AI from the data on this page and web research, with sources. Download it as PowerPoint to edit or as PDF to share.
- Executive summary and key facts
- Technology, with pictures of the device
- Clinical evidence and trials
- Regulatory history and safety
- Reimbursement, market and competition
- Risks, outlook and sources
AI-written from public data and may contain mistakes. Check each fact against its source before relying on it. Not investment, legal, reimbursement or medical advice.
FDA decisions
The newest 4 of 4 decisions filed under this name.
- Restylane® Lyft with LidocainePMA supplement
P040024-S146 · Decided Dec 23, 2025 · 21 days after receipt · Normal 180 Day Track No User Fee
Device type: Implant, dermal, for aesthetic use (LMH) · General & Plastic Surgery
3 more FDA decisions with a free account
Medicare coverage
National and local coverage documents whose titles match this device or its device type. Payment add-ons (NTAP, pass-through, TCET) and likely codes are covered in the summary above.
No Medicare coverage document has a title matching this device or device type. Many devices are paid under existing codes without one.
Clinical trials
Device studies on ClinicalTrials.gov that name "Restylane Lyft", any status and sponsor, newest update first.
Galderma R&DNot on our public-company list
NCT07566286 · 100 participants (planned) · Start Jun 3, 2026 · Primary completion Nov 1, 2027
Device: Restylane Lyft with Lidocaine · For: Chin Augmentation
Sites: Westport, Connecticut; Boynton Beach, Florida; Coral Gables, Florida · 8 sites in all
19 more trials with a free account
Adverse event reports (MAUDE)
Reports received since 2015 naming the brand "Restylane Lyft", and for the whole product code for context.
This brand
201 reports: 2 malfunction, 199 injury, 0 death
Whole product code LMH
16,542 reports: 1,388 malfunction, 15,105 injury, 12 death
Newest reports for this brand
9710154-2026-00115 · Received Oct 27, 2026 · Event dated Sep 25, 2026
Device type: Implant, Dermal, For Aesthetic Use (LMH)
Device problem as coded: Adverse Event Without Identified Device or Use Problem
Patient problem as coded: Obstruction/Occlusion; Reduced Blood Flow
4 more reports with a free account
Recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
No recall in FDA's data is linked to these FDA numbers.
Published research
The most relevant PubMed records for "Restylane Lyft"[tiab]. The summary above synthesizes these.
- Histological Evaluation of Restylane Lyft Used as a Scaffold for Dental Pulp Regeneration in Non-Infected Immature Teeth in Dogs.
AlHowaish NA, AlSudani DI, Khounganian R, et al. · Materials (Basel) · 2022
- Restylane Lyft for Aesthetic Shaping of the Nasal Dorsum and Radix: A Randomized, No-Treatment Control, Multicenter Study.
Wang X, Li B, Li Q · Plast Reconstr Surg · 2022Randomized Controlled Trial, Multicenter Study
- Thrombogenicity of Hyaluronic Acid Fillers: A Quantitative Thrombodynamics Study.
Kim JS, Gonzales L, Lester J, et al. · Ophthalmic Plast Reconstr Surg · 2022
- Evaluation of a hyaluronic acid hydrogel (Restylane Lyft) as a scaffold for dental pulp regeneration in a regenerative endodontic organotype model.
AlHowaish NA, AlSudani DI, AlMuraikhi NA · Odontology · 2022
- A multi-center comparative efficacy and safety study of two different hyaluronic acid fillers for treatment of nasolabial folds in a Chinese population.
Li D, Sun J, Wu S · J Cosmet Dermatol · 2019Comparative Study, Equivalence Trial
- Response of 21 Hyaluronic Acid Fillers to Recombinant Human Hyaluronidase.
Park KE, Mehta P, Kherani F, et al. · Plast Reconstr Surg Glob Open · 2023
- Does cannula's size alter rheological properties of hyaluronic acid filler?
Sisnando AL, Nayak VV, Câmara-Sousa MB, et al. · Int J Biol Macromol · 2024
- Differentiation of NASHA and OBT Hyaluronic Acid Gels According to Strength, Flexibility, and Associated Clinical Significance.
Ohrlund A, Winlof P, Bromee T, et al. · J Drugs Dermatol · 2024
- Comparison of the Degradability of Hyaluronic Acid by Ovine and Recombinant Human Hyaluronidase.
Safran T, Khalaf R, Metelitsa A, et al. · Aesthet Surg J · 2025Comparative Study
- How Much Does Filler Apparatus Influence Ease of Injection (and Hence, Potential Safety)?
Ginter A, Lee T, Woodward J · Ophthalmic Plast Reconstr Surg · 2023
- Effect of Stromal Vascular Fraction on Sustained Volume Retention of Five Different Hyaluronic Acid Fillers.
Koo HT, Zhang S, Jin US · Aesthetic Plast Surg · 2022
- The 5-Step Filler Hand Rejuvenation: Filling with Hyaluronic Acid.
Khosravani N, Weber L, Patel R, et al. · Plast Reconstr Surg Glob Open · 2019
Other devices of this type
Also filed under product code LMH.
- RADIESSE® Injectable ImplantMerz North America, Inc. · PMA 2026
- SculptraQ-Med AB · PMA 2024
- Belotero Balance Dermal FillerMerz North America, Inc. · PMA 2026
- Restylane Injectable GelQ-Med AB · PMA 2022
- Restylane® ContourQ-Med AB · PMA 2026
- Juvederm Voluma XCAllergan · PMA 2025
- Juvéderm Voluma XC, Vollure XC, Volbella XC, Volux XC, SkinviveAllergan · PMA 2026
- Belotero Balance (+) Lidocaine Dermal FillerMerz North America, Inc. · PMA 2025
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.